Mihai Gheorghiade mainly focuses on Heart failure, Internal medicine, Cardiology, Heart disease and Intensive care medicine. Mihai Gheorghiade works on Heart failure which deals in particular with Ejection fraction. In his study, Severity of illness is strongly linked to Surgery, which falls under the umbrella field of Internal medicine.
His work on Randomization expands to the thematically related Cardiology. His work carried out in the field of Heart disease brings together such families of science as Dobutamine, Mortality rate, Circulatory system, Disease and Etiology. His research integrates issues of Guideline, Epidemiology, MEDLINE and Emergency medicine in his study of Intensive care medicine.
His primary scientific interests are in Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction. In general Heart failure, his work in Tolvaptan is often linked to In patient linking many areas of study. His biological study spans a wide range of topics, including Placebo and Surgery.
The Cardiology study combines topics in areas such as Prospective cohort study and Blood pressure. His Intensive care medicine study incorporates themes from Epidemiology, MEDLINE, Drug development, Emergency medicine and Disease. His Ejection fraction study frequently draws parallels with other fields, such as Pulmonary wedge pressure.
His main research concerns Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction. His Heart failure study frequently involves adjacent topics like Clinical trial. His research investigates the connection between Internal medicine and topics such as Placebo that intersect with problems in Aliskiren.
His Cardiology research is multidisciplinary, incorporating perspectives in Diabetes mellitus, Tolerability, Interquartile range and Clinical endpoint. His Intensive care medicine study also includes
Mihai Gheorghiade spends much of his time researching Heart failure, Internal medicine, Cardiology, Ejection fraction and Intensive care medicine. His Heart failure research incorporates themes from Diabetes mellitus, Interquartile range and Clinical trial. His biological study deals with issues like Placebo, which deal with fields such as Randomized controlled trial.
His Cardiology research integrates issues from Disease progression, Tolerability, Proportional hazards model and Cohort study. His Ejection fraction research incorporates elements of Coronary artery disease, Surgery, Myocardial infarction and Atrial fibrillation. He combines subjects such as Endocrinology, Kidney disease, Cardiovascular agent and Comorbidity with his study of Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Kenneth Dickstein;Alain Cohen-Solal;Gerasimos Filippatos;John J V McMurray.
European Journal of Heart Failure (2008)
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
A. Hjalmarson;S. Goldstein;B. Fagerberg;H. Wedel.
The Lancet (1999)
The effect of digoxin on mortality and morbidity in patients with heart failure
G Perry;E Brown;R Thornton;T Shiva.
The New England Journal of Medicine (1997)
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.
Andrew P. Ambrosy;Gregg C. Fonarow;Javed Butler;Ovidiu Chioncel.
Journal of the American College of Cardiology (2014)
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness
James A. Hill;Daniel F. Pauly;Debra R. Olitsky;Stuart Russell.
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Marvin A. Konstam;Mihai Gheorghiade;John C. Burnett;Liliana Grinfeld.
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Robert W. Schrier;Robert W. Schrier;Peter Gross;Mihai Gheorghiade;Tomas Berl.
The New England Journal of Medicine (2006)
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Michael S. Cuffe;Robert M. Califf;Kirkwood F. Adams;Raymond Benza.
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
Gregg C. Fonarow;Wendy Gattis Stough;William T. Abraham;Nancy M. Albert.
Journal of the American College of Cardiology (2007)
Chronic Heart Failure in the United States A Manifestation of Coronary Artery Disease
Mihai Gheorghiade;Robert O. Bonow.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: